Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Approved for marketing × HER2-positive Breast Cancer × tucatinib × Clear all

Status

Recruiting 1 Not yet recruiting 1 Completed 1 Approved for marketing 1 Active not recruiting 1

Sponsor Class

Study Type

Expanded_access 1

Sponsor

Cancer Type

Conditions

HER2-positive Breast Cancer 1

Interventions

Trastuzumab 2 tucatinib 1 pertuzumab 1 margetuximab 1 Capecitabine 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04220203 2025-06-26

Treatment Protocol of Tucatinib With Capecitabine and Trastuzumab in Patients With Unresectable Previously Treated HER2+ Breast Cancer

Seagen Inc.

Approved for marketing

HER2-positive Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡